Advertisement

Posttransplant Hypertension

  • David A. Laskow
  • John J. Curtis

Abstract

The main cause of death in the general population is cardiovascular disease, for which hypertension is a significant risk factor. It is not surprising, therefore, to find that the principal cause of mortality in renal failure patients is cardiovascular disease and that cardiovascular deaths occur at a much earlier age than in the general population (1,2).

Keywords

Renal Blood Flow Renal Artery Stenosis Chronic Rejection Renal Vascular Resistance Afferent Arteriole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    US Renal Data System: USRDS 1990 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, August 1990.Google Scholar
  2. 2.
    Fabrega AJ, Lopez-Boado M, Gonzalez S: Problems in the long-term renal allograft recipient. Crit Care Clin 6: 979–1005, 1990.PubMedGoogle Scholar
  3. 3.
    Brunner FP, Broyer M, Brynger H, Challah S, Fassbinder W, Oules R, Rizzoni G, Selwood NH, Wing AJ: Combined report on regular dialysis and transplantation in Europe XV, 1984. In: AM Davison, PJ Guillov, eds, Proceedings of the European Dialysis and Transplant Association. Bailliere Tindal, London, pp 5–79, 1985.Google Scholar
  4. 4.
    Van Ypersele de Strihou C, Vereerstraeten P, Wauthier M, Toussaint C, Pirson Y, De Plaen JF, Vanherweghem JL, Dautrebande J, Kinnaert P, van Geertruyden J, Dupont E, Alexandre GP: Prevalence, etiology and treatment of late post-transplant hypertension. Adv Nephrol Necker Hosp 12: 41–60, 1983.Google Scholar
  5. 5.
    Luke RG, Curtis JJ, Jones P, Whelchel JD, Diethelm AG: Mechanisms of posttransplant hypertension. Am J Kidney Dis 5: A79–A84, 1985.PubMedGoogle Scholar
  6. 6.
    Cheigh JS: Hypertension in kidney transplant recipients. In: JS Cheigh, eds, Hypertension in Kidney Disease. Martinus Nijhoff, Boston, pp 115–146, 1986.CrossRefGoogle Scholar
  7. 7.
    Cheigh JS, Wang J, Fine P, et al.: Hypertension and decreased graft survival in long-term kidney transplant recipients (abstract). American Society of Nephrology, Washington, DC, 1984.Google Scholar
  8. 8.
    Knight RJ, Kerman RH, Welsh M, Golden D, Schoenberg L, Van Buren CT, Lewis RM, Kahan BD: Chronic rejection in primary renal allograft recipients under cyclosporineprednisone immunosuppressive therapy. Transplantation 51 (2): 355–359, 1991.PubMedCrossRefGoogle Scholar
  9. 9.
    Dubovsky EV, Curtis JJ, Luke RG, Jones P, Edwards SM, Keller F, Whelchel JD, Diethelm AG: Captopril as a predictor of curable hypertension in renal transplant recipients. Contrib Nephrol 56: 117–123, 1987.PubMedGoogle Scholar
  10. 10.
    Paul LC, Fellstrom B: Chronic vascular rejection of the heart and the kidney-have rational treatment options emerged? (review). Transplantation 53 (6): 1169–1179, 1992.PubMedCrossRefGoogle Scholar
  11. 11.
    Gaston RS: Hypertension in the renal transplant recipient. In: Shaul, Massry, Glassock,eds, Massry and Glassock’s Textbook of Nephrology. 3rd ed. Williams and Wilkins, Baltimore, 1995.Google Scholar
  12. 12.
    Curtis JJ: Distinguishing the causes of post-transplantation hypertension. Pediatr Nephrol 5: 108–111, 1991.PubMedCrossRefGoogle Scholar
  13. 13.
    Gunnells JC Jr, Stickel DL, Robinson RR: Episodic hypertension associated with positive renin assays after renal transplantation. N Engl J Med 274: 543–547, 1966.PubMedCrossRefGoogle Scholar
  14. 14.
    Curtis JJ: Hypertension: a common problem for kidney transplant patients. Kidney 18 (2): 5, 1985.Google Scholar
  15. 15.
    Remuzzi G, Bertani T: Renal vascular and thrombotic effects of cyclosporine (review). Am J Kidney Dis 13 (4): 261–272, 1989.PubMedGoogle Scholar
  16. 16.
    Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441–449, 1972.PubMedCrossRefGoogle Scholar
  17. 17.
    Vertes V, Cangiano JL, Berman LB, Gould A: Hypertension in end-stage renal disease. N Engl J Med 280: 978–981, 1969.PubMedCrossRefGoogle Scholar
  18. 18.
    Curtis JJ, Luke RG, Diethelm AG, Whelchel JD, Jones P: Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 2 (8458): 739–742, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    The 13th report of the human renal transplant registry. Transplant Proc 9 (1): 9–26, 1977.Google Scholar
  20. 20.
    Haber E: The renin-angiotensin system and hypertension (review). Kidney Int 15 (4): 427–444, 1979.PubMedCrossRefGoogle Scholar
  21. 21.
    Mimran A, Mourad G, Ribstein J: The renin-angiotensin system and renal function in kidney transplantation. Kidney Int Suppl 30: S114–S117, 1990.PubMedGoogle Scholar
  22. 22.
    Coffman TM, Himmelstein S, Best C, Klotman PE: Post-transplant hypertension in the rat: effects of captopril and native nephrectomy. Kidney Int 36: 35–40, 1989.PubMedCrossRefGoogle Scholar
  23. 23.
    Curtis JJ: Cyclosporine and. hypertension. Clin Transplant 4: 337–340, 1990.Google Scholar
  24. 24.
    Curtis JJ, Lucas BA, Kotchen TA, Luke RG: Surgical therapy for persistent hypertension after renal transplantation. Transplantation 31 (2): 125–128, 1981.PubMedCrossRefGoogle Scholar
  25. 25.
    Converse RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327(27):19121918, 1992.Google Scholar
  26. 26.
    Gaston RS, Julian BA, Diethelm AG, Curtis JJ: Effects of enalapril on erythrocytosis after renal transplantation. Ann Intern Med 115: 954–955, 1991.PubMedCrossRefGoogle Scholar
  27. 27.
    Ettenger RB, Mark J, Grimm P: The impact of recombined human erythropoietin therapy on renal transplantation. Am J Kidney Dis 18 (4 Suppl 1): 57–61, 1991.PubMedGoogle Scholar
  28. 28.
    Tilney NL, Rocha A, Strom TB, Kirkman RL: Renal artery stenosis in transplant patients. Ann Surg 199: 454–460, 1984.PubMedCrossRefGoogle Scholar
  29. 29.
    Lacombe M: Arterial stenosis complicating renal allotransplantation in man: a study of 38 cases. Ann Surg 181: 283–288, 1975.PubMedCrossRefGoogle Scholar
  30. 30.
    Benoit G, Moukarzel M, Hiesse C, Verdelli G, Charpentier B, Fries D: Transplant renal artery stenosis: experience and comparative results between surgery and angioplasty. Transplant Int 3: 137–140, 1990.Google Scholar
  31. 31.
    Roberts JP, Ascher NL, Fryd DS, Hunter DW, Dunn DL, Payne WD, Sutherland DE, Castaneda-Zuniga W, Najarian JS: Transplant renal artery stenosis. Transplantation 48 (4): 580–583, 1989.PubMedGoogle Scholar
  32. 32.
    Morris PJ, Yadav RV,Kincaid-Smith P, Anderton J, Hare WS, Johnson N, Johnson W, Marshall VC: Renal artery stenosis in renal transplantation. Med J Aust 1: 1255–1257, 1971.PubMedGoogle Scholar
  33. 33.
    Trompeter RS, Bewick M, Haycock GB, Chantier C: Renal transplantation in very young children. Lancet 1(8321):373375, 1983.Google Scholar
  34. 34.
    Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, Dustan HP: Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med 308: 377–381, 1983.PubMedCrossRefGoogle Scholar
  35. 35.
    Hricik DE: Antihypertensive and renal effects of enalapril in post-transplant hypertension. Clin Nephrol 27: 250–259, 1987.PubMedGoogle Scholar
  36. 36.
    Myers BD, Sibley R, Newton L, et al.: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33 (2): 590–600, 1988.PubMedCrossRefGoogle Scholar
  37. 37.
    Ahmad T, Coulthard MG, Eastham EJ: Reversible renal failure due to the use of captopril in a renal allograft recipient treated with cyclosporine. Nephrol Dial Transplant 4: 31 1312, 1989.Google Scholar
  38. 38.
    Murray BM, Venuto RC, Kohli R, Cunningham EE: Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine. Am J Kidney Dis 16 (1): 66–69, 1990.PubMedGoogle Scholar
  39. 39.
    Davin JC, Mahieu PR: Captopril-associated renal failure with endarteritis but not renal artery stenosis in transplant recipient. Lancet 1 (8432): 820, 1985.PubMedCrossRefGoogle Scholar
  40. 40.
    Erley CM, Duda SH, Wakat JP, Sokler M, Reuland P, Muller-Schauenburg W, Schareck W, Lauchart W, Risler T: Noninvasive procedures for diagnosis of renovascular hypertension in renal transplant recipients-a prospective analysis. Transplantation 54: 863–867, 1992.PubMedCrossRefGoogle Scholar
  41. 41.
    Munda R, Alexander JW, Miller S, First MR, Fidler JP: Renal allograft artery stenosis. Am J Surg 134: 400–403, 1977.PubMedCrossRefGoogle Scholar
  42. 42.
    Macia M, Paez A, Tornero F, De Oleo P, Hidalgo L, Barrientos A: Post-transplant renal artery stenosis: a possible immunological phenomenon. J Urol 145: 251–252, 1991.PubMedGoogle Scholar
  43. 43.
    McMullin ND, Reidy FJ, Koffman CG, Rigden SP, Haycock G, Chantler C, Bewick M: The management of renal transplant artery stenosis in children by percutaneous transluminal angioplasty. Transplantation 53 (3): 559–563, 1992.PubMedCrossRefGoogle Scholar
  44. 44.
    Sawaya B, Provenzano R, Kupin WL, Venkat KK: Cyclosporine-induced renal macroangiopathy. Am J Kidney Dis 12 (6): 534–537, 1988.PubMedGoogle Scholar
  45. 45.
    Kornerup HJ, Pedersen EB, Fjeldborg O: Kidney transplant artery stenosis. Interrelationship between blood pressure, kidney function, renin-aldosterone system and body sodium content. Proc Eur Dial Transplant Assoc 14: 377–385, 1977.PubMedGoogle Scholar
  46. 46.
    Pollini J, Guttman RD, Beaudoin JG, Morehouse DD, Klassen J, Knaack J: Late hypertension following renal allotransplantation. Clin Nephrol 11: 202–212, 1979.PubMedGoogle Scholar
  47. 47.
    Sniderman RW, Sprayregen S, Sos TA, Saddekni S, Hilton S, Mollenkopf F, Soberman R, Cheigh JS, Tapia L, Stubenbord W Jr, Tellis V, Veith FJ: Percutaneous transluminal dilation in renal transplant arterial stenosis. Transplantation 30: 440444, 1980.Google Scholar
  48. 48.
    Lohr JW, MacDougall ML, Chonko AM, Diederich DA, Grantham JJ, Savin VJ, Wiegmann TB: Percutaneous transluminal angioplasty in transplant renal artery stenosis: experience and review of the literature. Am J Kidney Dis 7 (5): 363–367, 1986.PubMedGoogle Scholar
  49. 49.
    Thomas CP, Riad H, Johnson BF, Cumberland DC: Percutaneous transluminal angioplasty in transplant renal arterial stenoses: a long-term follow-up. Transplant Int 5: 129–132, 1992.CrossRefGoogle Scholar
  50. 50.
    Greenstein SM, Verstandig A, McLean GK, Dafoe DC, Burke DR, Meranze SG, Naji A, Grossman RA, Perloff LJ, Barker CF: Percutaneous transluminal angioplasty, the procedure of choice in the hypertensive renal allograft recipient with renal artery stenosis. Transplantation 43: 29–32, 1987.PubMedCrossRefGoogle Scholar
  51. 51.
    Popovtzer MM, Pinnggera W, Katz FH, Corman JL, Roninette J, Lanois B, Haglrimson CG, Starzel TE: Variations in arterial blood pressure after kidney transplantation. Relation to renal function, plasma renin activity, and the dose of prednisone. Circulation 47: 1297–1305, 1973.PubMedCrossRefGoogle Scholar
  52. 52.
    Whitworth JA, Gordon D, Andrews J, Scoggins BA: The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 7 (7): 537–549, 1989.PubMedCrossRefGoogle Scholar
  53. 53.
    Sampson D, Albert DJ: Alternate-day therapy with methylprednisolone after renal transplantation. J Urol 109(3):345348, 1973.Google Scholar
  54. 54.
    Jackson SH, Beevers DG, Myers K: Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Colch) 61 (Suppl 7): 381s–383s, 1981.Google Scholar
  55. 55.
    McHugh MI, Tanboga H, Marcen R, Liano F, Robson V, Wilkinson R: Hypertension following renal transplantation: the role of the host’s kidney. Q J Med 49 (196): 395–403, 1980.PubMedGoogle Scholar
  56. 56.
    Cohen SL: Hypertension in renal transplant recipients: role of bilateral nephrectomy. Br Med J 3 (871): 78–81, 1973.PubMedCrossRefGoogle Scholar
  57. 57.
    Hall JE, Morse CL, Smith MJ, Young DB, Guyton AC: Control of arterial pressure and renal function during glucocorticoid excess in dogs. Hypertension 2 (2): 139–148, 1980.PubMedCrossRefGoogle Scholar
  58. 58.
    Suzuki H, Shibata H, Murakami M, Nakamoto H, Kondo K, Saruta T: Case report: hypertension in Cushing’s syndrome. Am J Med Sci 303: 329–332, 1992.PubMedCrossRefGoogle Scholar
  59. 59.
    Curtis JJ, Galla JH, Kotchen TA, Lucas B, McRoberts JW, Luke RG: Prevalence of hypertension in a renal transplant population on alternate-day steroid therapy. Clin Nephrol 5 (3): 123–127, 1976.PubMedGoogle Scholar
  60. 60.
    Siegel RR, Luke RG, Hellebusch AA: Reduction of toxicity of corticosteroid therapy after renal transplantation. Am J Tiller DJ: Influ-Med 53 (2): 159–169, 1972.Google Scholar
  61. 61.
    McDonald JC, Bethea MC, Lindsey ES, Gonzalez FM, Garbus SB: Hypertension and renin activity in human renal transplantation. Ann Surg 179: 580–586, 1974.PubMedCrossRefGoogle Scholar
  62. 62.
    Curtis JJ, Luke RG, Jones P, Diethelm AG, Whelchel JD: Hypertension after successful renal transplantation. Am J The renin angio-Med 79: 193–200, 1985.Google Scholar
  63. 63.
    Wauthier M, Vereerstraeten P, Pirson Y, Toussaint C, Alexandre GP, Kinnaert P, Van Geertruyden H, van Ypersele de Strihou C: Prevalence and causes of hyperten sion late after renal transplantation. Proc Eur Dial Trans- plant Assoc 19: 566–571, 1983.Google Scholar
  64. 64.
    Curtis JJ, Luke RG, Jones P, Diethelm AG: Hypertension in F, Zukovskacyclosporine-treated renal transplant recipients is sodium de pendent. Am J Med 85: 134–138, 1988.PubMedCrossRefGoogle Scholar
  65. 65.
    Mihatsch MJ, Thiel G, Ryffel B: Histopathology of cyclosporine nephrotoxicity. Transplant Proc 20 (3 Suppl 3): 759–771, 1988.PubMedGoogle Scholar
  66. 66.
    Bantle JP, Boudreau RJ, Ferris TF: Suppression of plasma renin activity by cyclosporine. Am J Med 83: 59–64, 1987.PubMedCrossRefGoogle Scholar
  67. 67.
    Stanek B, Kovarik J, Rasoul-Rockenschaub S, Silberbauer K: Renin-angiotensin-aldosterone system and vasopressin in cyclosporine-treated renal allograft recipients. Clin Nephrol 28: 186–189, 1987.PubMedGoogle Scholar
  68. 68.
    Bellet M, Cabrol C, Sassano P, Leger P, Corvol P, Menard J: Systemic hypertension after cadaveric transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone sys- tern. Am J Cardiol 56: 927–931, 1985.PubMedCrossRefGoogle Scholar
  69. 69.
    English J, Evan A, Houghton DC, Bennett WM: Cyclosporine-induced acute renal dysfunction in the rat. Evi dence of arteriolar vasoconstriction with preservation of tu- bular function. Transplantation 44: 135–141, 1987.PubMedCrossRefGoogle Scholar
  70. 70.
    Murray BM, Paller MS, Ferris TF: Effect of cyclosporine. administration on renal hemodynamics in conscious rats. 87 Kidney Int 28: 767–774, 1985.PubMedCrossRefGoogle Scholar
  71. 71.
    Youngelman DF, Kahng KU, Rosen BD, Dresner LS, Wait RB: Effects of chronic cyclosporine administration on renal blood flow and intrarenal blood flow distribution. Transplan- tation 51 (2): 503–509, 1991.CrossRefGoogle Scholar
  72. 72.
    Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P: Cyclosporine in therapeutic doses increases renal allograft vascular resistance. Lancet 2 (8505): 477–479, 1986.PubMedCrossRefGoogle Scholar
  73. 73.
    Cunningham C, Gavin MP, Whitney PH, Burke MD, Macintyre F, Thomson AW, Simpson JG: Serum cyclosporin levels, hepatic drug metabolism and renal tubulotoxicity. Biochem Pharmacol 33(18):2857-2861,1984.Google Scholar
  74. 74.
    Paller MS, Murray BM: Renal dysfunction in animal models in cyclosporineof cyclosporine toxicity. Transplant Proc 17(4) (Suppl 1 ): 155 159, 1985.Google Scholar
  75. 75.
    Baxter CR, Duggin GG, Hall BM, Horvath JS, Tiller DJ: Stimulation of renin release from rat renal cortical slices by cyclosporin A. Res Commun Chem Pathol Pharmacol 43 (3): 417–423, 1984.PubMedGoogle Scholar
  76. 76.
    Perico N, Benigni A, Bosco E, Rossini M, Orisio S, Ghilardi F, Piccinelli A, Remuzzi G: Acute cyclosporine A nephrotoxicity in rats: which role for the renin-angiotensin system and glomerular prostaglandins? Clin Nephrol 25 (Suppl 1): S83–S88, 1986.PubMedGoogle Scholar
  77. 77.
    Nahman NS Jr, Cosio FG, Mahan JD, Henry ML, Ferguson RM: Cyclosporine nephrotoxicity in spontaneously hyper tensive rats. Transplantation 45: 768–772, 1988.PubMedCrossRefGoogle Scholar
  78. 78.
    Duggin GG, Baxter C, Hall BM, Horvath JS, ence of cyclosporine A (CSA) on intrarenal control of GFR. Clin Nephrol 25 (Suppl 1): S43–S45, 1986.PubMedGoogle Scholar
  79. 79.
    Klassen DK, Solez K, Burdick JF: Effects of cyclosporine on human renal allograft renin and prostaglandin production. Transplantation 47: 1072–1075, 1989.PubMedCrossRefGoogle Scholar
  80. 80.
    Sturrock NDC, Lang CC, Struther AD: tensin axis is suppressed after initiation of cyclosporine in man (abstract). In: HE Eliahous, A Lasna, Y Bar-khayim, eds, XIIth International Congress of Nephrology, Jerusalem, Israel, p 542, June 1993.Google Scholar
  81. 81.
    Curtis JJ: Hypertension and kidney transplantation. Curr Opin Nephrol Hypertensi 1: 100–105, 1992.CrossRefGoogle Scholar
  82. 82.
    Nieszporek T, Grzeszczak W, Kokot Szczechowska E, Wiecek A, Kusmierski S, Szkodny A: Does the kind of immunosuppressive therapy influence plasma renin activity, aldosterone and vasopressin in patients with a kidney transplant? Int Urol Nephrol 21: 233–240, 1989.PubMedCrossRefGoogle Scholar
  83. 83.
    Zukowska-Szczechowska E, Kokot F, Grzeszczak W, Wocial B: Plasma levels of adrenaline and noradrenaline, plasma renin activity and arterial blood pressure in patients after kidney transplantation. (Polish). Pol Arch Med Wewn 86 (4): 254–262, 1991.PubMedGoogle Scholar
  84. 84.
    Coffman TM, Carr DR, Yarger WE, Klotman PE: Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 43: 282–285, 1987.PubMedCrossRefGoogle Scholar
  85. 85.
    Deray G, Le Hoang P, Cacoub P, et al.: Effects of cyclosporine on plasma renin activity, catecholamines and prostaglandins in patients with idiopathic uveitis. Am J Nephrol 8: 298–304, 1988.PubMedCrossRefGoogle Scholar
  86. 86.
    Tresham JJ, Whitworth JA, Scoggins BA, Bennett WM: Cyclosporine-induced hypertension in sheep. The role of thromboxanes. Transplantation 49 (1): 144–148, 1990PubMedCrossRefGoogle Scholar
  87. 87.
    Wilkie ME, Beer JC, Newman D, Raftery MJ, Marsh FP: Evidence that the risks of misoprostol outweight its benefits in stable cyclosporine-treated renal allograft recipients. Transplantation 54 (3): 565–567, 1992.PubMedCrossRefGoogle Scholar
  88. 88.
    Boers M. Bensen WG, Ludwin D, Goldsmith CH, Tugwell P:Cyclosporine nephrotoxicity in rheumatoid arthritis: no ef of short term misoprostol treatment. J Rheumatol fect 19: 534–537, 1992.Google Scholar
  89. 89.
    Gladue RP, Newborg MF: The protective effects of the thromboxane synthetase inhibitor Dazmegrel on nephrotoxicity in cyclosporine-treated rats. Transplantation 52 (5): 837–841, 1991.PubMedCrossRefGoogle Scholar
  90. 90.
    Weir MR, Klassen DK, Burdick JF: A pilot study to assess the ability of an orally available selective thromboxane synthase inhibitor to improve renal function treated renal transplant recipients. J Am Soc Nephrol 2: 1285–1290, 1992.PubMedGoogle Scholar
  91. 91.
    Adams MB: Enisoprost in renal transplantation. The Enisoprost Renal Transplant Study Group. Transplantation 53: 338–345, 1992.PubMedCrossRefGoogle Scholar
  92. 92.
    Mason J: The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol 4: 686–704, 1990.PubMedCrossRefGoogle Scholar
  93. 93.
    Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL: Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 37: 1487–1491, 1990.PubMedCrossRefGoogle Scholar
  94. 94.
    Awazu M, Sugiura M, Inagami T, Ichikawa I, Kon V: Cyclosporine promotes glomerular endothelin binding in vivo. J Am Soc Nephrol 1: 1253–1258, 1991.PubMedGoogle Scholar
  95. 95.
    Bunchman TE, Brookshire CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 88 (1): 310–314, 1991.PubMedCrossRefGoogle Scholar
  96. 96.
    Perico N, Ruggenenti P, Gaspar F, Mosconi L, Benigni A, Amuchastegui CS, Gasparini F, Remuzzi G: Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 54 (1): 56–60, 1992.PubMedCrossRefGoogle Scholar
  97. 97.
    Diederich D, Yang Z, Luscher TF: Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 2 (8): 1291–1297, 1992.PubMedGoogle Scholar
  98. 98.
    Curtis JJ, Laskow DA, Jones PA, Julian BA, Gaston RS, Luke RG: Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 3: 1570–1574, 1993.PubMedGoogle Scholar
  99. 99.
    Copur MS, Tasdemir I, Turgan C, Yasavul U, Caglar S: Effects of nitrendipine on blood pressure and blood ciclosporine A level in patients with posttransplant hypertension. Nephron 52: 227–230, 1989.PubMedCrossRefGoogle Scholar
  100. 100.
    Berg KJ, Holdaas H, Endresen L, Fauchald P, Hartmann A, Pran T, Solbu D: Effect of isradipine on renal function in cyclosporine-treated renal transplant patients. Nephrol Dial Transplant 6: 725–730, 1991.PubMedCrossRefGoogle Scholar
  101. 101.
    Moss NG, Powell SL, Falk RJ: Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci USA 82: 8222–8226, 1985.PubMedCrossRefGoogle Scholar
  102. 102.
    Lyson T, McMullan DM, Ermel LD, Morgan BJ, Victor RG: Mechanism of cyclosporine-induced sympathetic activation and acute hypertension in rats. Hypertension 23 (5): 667–675, 1994.PubMedCrossRefGoogle Scholar
  103. 103.
    Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, Hanson P, Mohanty PK, Victor RG: Cyclosporineinduced sympathetic activation and hypertension after heart transplantation. N Engl J Med 323 (11): 693–699, 1990.PubMedCrossRefGoogle Scholar
  104. 104.
    Kino T, Hatanaka H, Miyata S, et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 40: 1256–1265, 1987.CrossRefGoogle Scholar
  105. 105.
    Harding MW, Galat A, Uehling DE, Schreiber SL: A receptor for the immunosuppressant FK506 is a cis-trans peptidylprolyl isomerase. Nature 341 (6244): 758–760, 1989.PubMedCrossRefGoogle Scholar
  106. 106.
    Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341 (6244): 755–757, 1989.PubMedCrossRefGoogle Scholar
  107. 107.
    Clipstone NA, Crabtree GR: Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357 (6380): 695–697, 1992.PubMedCrossRefGoogle Scholar
  108. 108.
    O’Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O’Neill EA: FK506- and CsA-sensitive activation of the interleukin-2 promoter by calcineruin. Nature 357 (6380): 692–694, 1992.PubMedCrossRefGoogle Scholar
  109. 109.
    Liu J, Albers MW, Wandless TJ, Luan S, Alberg DG, Belshaw PJ, Cohen P, MacKintosh C, Klee CB, Schreiber SL: Inhibition of T cell signaling by immunophilin–ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 31: 3896–3901, 1992.PubMedCrossRefGoogle Scholar
  110. 110.
    DeFranco AL: Signal transduction. Immunosuppressants at work. Nature 352 (6338): 754–755, 1991.CrossRefGoogle Scholar
  111. 111.
    McCaffrey PG, Perrino BA, Soderling TR, Rao A: NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J Biol Chem 268: 3747–3752, 1993.PubMedGoogle Scholar
  112. 112.
    Lyson T, Ermel LD, Belshaw PJ, Alberg DG, Schreiber SL, Victor RG: Cyclosporine-and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. Circ Res 73 (3): 596–602, 1993.PubMedCrossRefGoogle Scholar
  113. 113.
    Curtis JJ, Laskow DA, Jones PA: Sodium sensitivity of blood pressure: FK506 compared to CSA treated renal transplant recipients (Abstract). American Society of Transplant Physicians, 13th Annual Meeting, p 90, 1994.Google Scholar
  114. 114.
    Yamada K, Sugisaki Y, Akimoto M, Yamanaka N: FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney—morphologic and biologic analysis. Transplant Proc 24: 1396–1398, 1992.PubMedGoogle Scholar
  115. 115.
    Moutabarrik A, Ishibashi M, Fukunaga M, et al.: FK506induced kidney tubular cell injury. Transplantation 54: 1041 1047, 1992.Google Scholar
  116. 116.
    Benigni A, Chiabrando C, Piccinelli A, Perico N, Gavinelli M,Furci L, Patino O, Abbate M, Bertani T, Remuzzi G: Increased urinary excretion of thromboxane B2 and 2,3dinor-TxB2 in cyclosporine A nephrotoxicity. Kidney Int 34: 164–174, 1988.PubMedCrossRefGoogle Scholar
  117. 117.
    Shapiro R, Jordan M, Fung J, McCauley J, Johnston J, Iwaki Y, Tzakis A, Hakala T, Todo S, Starzl TE: Kidney transplantation under FK 506 immunosuppression. Transplant Proc 23 (1 Pt 1): 920–923, 1991.PubMedGoogle Scholar
  118. 118.
    Fung J, Abu-Elmagd K, Jain A, et al.: A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 23 (6): 2977–2983, 1991.PubMedGoogle Scholar
  119. 119.
    Armitage JM, Kormos RL, Fung J, et al.: Preliminary experience with FK506 in thoracic transplantation. Transplantation 52 (1): 164–167, 1991.PubMedCrossRefGoogle Scholar
  120. 120.
    Demetris AJ, Fung JJ, Todo S, McCauley J, Jain A, Takaya S, Alessiani M, Abu-Elmagd K, Van Thiel DH, Starzl TE: Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy—a clinicopathologic study in 96 patients. Transplantation 53: 1056–1062, 1992.PubMedCrossRefGoogle Scholar
  121. 121.
    Tzakis AG, Fung JJ, Todo S, Reyes J, Green M, Starzl TE: Use of FK 506 in pediatric patients. Transplant Proc 23 (1, Pt 2): 924–927, 1991.PubMedGoogle Scholar
  122. 122.
    Klintmalm GB, Goldstein R, Gonwa T, et al.: Use of FK506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. Transplant Proc 25 (1, Pt 1): 635–637, 1993.PubMedGoogle Scholar
  123. 123.
    Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A: Phase II FK506 multicenter concentration control study: one-year follow-up. Transplant Proc,in press.Google Scholar
  124. 124.
    Mourad G, Ribstein J, Mimran A: Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 43 (2): 419–425, 1993.PubMedCrossRefGoogle Scholar
  125. 125.
    Sorensen SS, Skovbon H, Eiskjaer H, Thomsen K, Pedersen EB: Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporine-treated renal transplant recipients. Nephrol Dial Transplant 7: 69–78, 1992.PubMedGoogle Scholar
  126. 126.
    Feehally J, Walls J, Mistry N, Horsburgh T, Taylor J, Veitch PS, Bell PR: Does nifedipine ameliorate cyclosporine A nephrotoxicity? Br Med J (Clin Res Ed) 295 (6593): 310, 1987.CrossRefGoogle Scholar
  127. 127.
    Corteza Q, Shen S, Revie D, Chretien P: Effect of calcium channel blockers on in vivo cellular immunity in mice. Transplantation 47 (2): 339–342, 1989.PubMedCrossRefGoogle Scholar
  128. 128.
    Howard RL, Shapiro JI, Babcock S, Chan L: The effect of calcium channel blockers on the cyclosporine dose requirement in renal transplant recipients. Ren Fail 12 (2): 89–92, 1990.PubMedCrossRefGoogle Scholar
  129. 129.
    Endresen L, Bergan S, Holdaas H, Pran T, Sinding-Larsen B, Berg KJ: Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. Ther Drug Monit 13 (6): 490–495, 1991.PubMedCrossRefGoogle Scholar
  130. 130.
    Laskow DA, Curtis JJ, Luke RG, Julian BA, Jones P, Deierhoi MH, Barber WH, Diethelm AG: Cyclosporineinduced changes in glomerular filtration rate and urea excretion. Am J Med 88 (5): 497–502, 1990.PubMedCrossRefGoogle Scholar
  131. 131.
    Curtis JJ: Hypertension and kidney transplantation. Am J Kidney Dis 7 (3): 181–196, 1986.PubMedGoogle Scholar
  132. 132.
    Tiller DJ, Hall BM, Horvarth JS, Duggin GG, Thompson JF, Sheil AG: Gout and hyperuricaemia in patients onGoogle Scholar
  133. cyclosporin and diuretics (letter). Lancet 1 (8426): 453, 1985.Google Scholar
  134. 133.
    Pollak R, Maddux MS, Cohan J, Jacobsson PK, Mozes MF: Erythrocythemia following renal transplantation: influence of diuretic therapy. Clin Nephrol 29 (3): 119–123, 1988.PubMedGoogle Scholar
  135. 134.
    Sanders CE, Curtis JJ, Julian BA, Gaston RS, Jones PA, Laskow DA, Deierhoi MH, Barber WH, Diethelm AG: Tapering or discontinuing cyclosporine for financial reasons—a single-center experience. Am J Kidney Dis 21 (1): 9–15, 1993.PubMedGoogle Scholar
  136. 135.
    Flechner SM, Lorber M, Van Buren C, Kerman R, Kahan BD: The case against conversion to azathioprine in cyclosporine-treated renal recipients. Transplant Proc 17(4) (Suppl 1 ): 276–281, 1985.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • David A. Laskow
    • 1
  • John J. Curtis
    • 2
  1. 1.Department of SurgeryUniversity of Alabama-BirminghamBirminghamUSA
  2. 2.Department of MedicineUniversity of Alabama-BirminghamBirminghamUSA

Personalised recommendations